BioStock: Cereno Scientific drives a paradigm shift in CVD

Cardiovascular disease is the number one killer in the world, and conventional treatments are simply not enough. A review published in the Lancet Healthy Longevity last week describes the benefits of epigenetic modulation in treating some of the major pathophysiological mechanisms of cardiovascular disease, and how it opens up for new opportunities for within a broad spectrum of diseases, even beyond cardiovascular disease. In Sweden, biotech Cereno Scientific has already begun taking advantage of such opportunities and developed a strong drug development portfolio around epigenetic modulation. BioStock takes a closer look.

Read the full article at biostock.se:

https://www.biostock.se/en/cereno-scientific-drives-a-paradigm-shift-in-cvd/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se